Health

#SPRS2303285AOrder of January 31, 2023 clarifying situations for pharmacist substitution within a hybrid group

🇫🇷France··Other·Medium Impact·View source ↗

AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.

🇬🇧 English

This law outlines the medical situations where pharmacists in France can substitute medications within a hybrid group. It aims to clarify when substitutions are permissible, making it easier for pharmacists to manage patient prescriptions effectively.

AI-generated summary. May contain errors. Refer to official sources for legal decisions.

Key Changes

  • Pharmacists can substitute medications within specified medical situations
  • Clarifies conditions for substitution within hybrid groups
  • Aims to streamline prescription management

Obligations

What this law requires

high

Pharmacists in hybrid groups must apply the medical situations listed in the Annex when determining whether medication substitution is permissible

Pharmacists operating within hybrid groups in France
operational
high

Pharmacists must not perform medication substitutions outside the medical situations defined in the Annex, except as otherwise permitted by the Order of January 31, 2023

Pharmacists operating within hybrid groups in France
prohibition
high

Substitutions for ATC Class R03A medications may be performed by the pharmacist in all medical situations

Pharmacists operating within hybrid groups in France
operational
high

Substitutions for ATC Class R03B medications may be performed by the pharmacist in all medical situations

Pharmacists operating within hybrid groups in France
operational
medium

The Director General of Health and the Director of Social Security must ensure execution of this order within their respective areas of responsibility

Director General of Health (France), Director of Social Security (France)
operational

Affected Parties

PharmacistsPatients

Tags

pharmacy,medication substitution,healthcare regulation